NCT00122564View on ClinicalTrials.gov

Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers

PHASE1TerminatedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

April 30, 2005

Conditions

HIV Infections

Interventions

BIOLOGICAL

HIV-1 gp 160

BIOLOGICAL

DC-Chol

Trial Locations (1)

75012

Hopital Tenon, Paris

Sponsors

Collaborators (1)

Aventis Pharmaceuticals

All Listed Sponsors

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV